top of page

Medigene Presents at CAR-TCR Summit Europe Showcasing Unique Approach for Development of Differentia

Planegg/Martinsried, February 29, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today highlighted recent updates on the progress made within key areas of its proprietary End-to-End Platform, at the 7th CAR-TCR Summit Europe taking place in London from… Medigene Presents at CAR-TCR Summit Europe Showcasing Unique Approach for Development of Differentiated TCR-T Therapies

Aktuelle Beiträge

Alle ansehen

Comentários


bottom of page